PRAGUE / BRUSSELS, April 27, 2026

Zentiva has filed an appeal before the Court of Justice of the European Union (CJEU) challenging key aspects of the Urban Wastewater Treatment Directive (UWWTD), raising concerns over its potential impact on medicine affordability, accessibility, and supply across Europe. The appeal seeks to overturn an earlier inadmissibility ruling and enable a full judicial review of the Directive, which imposes extended producer responsibility (EPR) obligations on pharmaceutical and cosmetic manufacturers. This move highlights growing industry concerns about regulatory frameworks that may unintentionally disrupt healthcare systems while aiming to address environmental challenges.

Regulatory Challenge Highlights Industry Concerns

The appeal centers on the Directive’s EPR scheme, which requires pharmaceutical producers to bear at least 80% of the costs associated with advanced wastewater treatment, regardless of their actual contribution to micropollution. Zentiva argues that this approach violates the “polluter pays” principle by disproportionately targeting medicine manufacturers, while other contributing industries are not equally held accountable.

The Directive has already sparked widespread concern among EU Member States, with 24 out of 27 countries expressing doubts or requesting clarification regarding its implementation and impact. Despite these concerns, the policy is moving forward at the national level, prompting pharmaceutical companies to seek legal recourse to protect both industry sustainability and patient access to essential medicines.

Impact on Medicine Access and Healthcare Systems

Advertisement

cGxPJobs Banner

Zentiva emphasizes that generic medicines, which account for approximately 70% of all medicines dispensed in Europe, operate under strict pricing regulations and low profit margins, limiting their ability to absorb additional costs imposed by the Directive. The company warns that increased financial burden could lead to reduced supply, higher healthcare costs, and potential medicine shortages, ultimately affecting millions of patients who rely on affordable treatments.

The Directive’s current structure does not incentivize the development of environmentally sustainable medicines, as pharmaceutical reformulation requires extensive research, regulatory approval, and long development timelines. As a result, the policy may increase costs without delivering meaningful environmental benefits, creating unintended consequences for both the healthcare system and the pharmaceutical industry.

Balancing Environmental Goals with Public Health

While reaffirming its commitment to environmental sustainability, Zentiva advocates for a more balanced regulatory approach that aligns environmental objectives with public health priorities, ensuring that efforts to reduce pollution do not compromise access to essential medicines. The company’s appeal challenges specific provisions of the Directive, including cost allocation mechanisms outlined in Articles 9 and 10, seeking a fair and proportionate framework that reflects actual environmental contributions.

From a cGxP and regulatory perspective, this case underscores the complex interplay between environmental policy and pharmaceutical compliance, highlighting the need for regulations that support both sustainability and healthcare system resilience. Zentiva’s position reflects a broader industry call for policy refinement that safeguards patient access while maintaining environmental responsibility.

Source: Zentiva press release